Haemostasis in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 29, Issue 1, 2014, Pages 29-40

  Lutz, Jens ^a   Menke, Julia ^a   Sollinger, Daniel ^a   Schinzel, Helmut ^a   Thürmel, Klaus ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

bleeding disorders; chronic kidney disease; haemostasis; thrombophilia; uraemia

Indexed keywords

HEPARIN; MICRORNA; PHOSPHOLIPID ANTIBODY;

ACTIVATING CLOTTING TIME; ANEMIA; ANTICOAGULANT THERAPY; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD VESSEL WALL; CELL INTERACTION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC TEST; ENDOTHELIUM; HEMODIALYSIS; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MEMBRANE MICROPARTICLE; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOEMBOLISM; THROMBOSIS; VASCULAR ACCESS; VASCULAR ACCESS THROMBOSIS;

BLEEDING DISORDERS; CHRONIC KIDNEY DISEASE; HAEMOSTASIS; THROMBOPHILIA; URAEMIA;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HEMORRHAGE; HEMOSTASIS; HUMANS; OXIDATIVE STRESS; RENAL INSUFFICIENCY; RENAL INSUFFICIENCY, CHRONIC; THROMBOSIS;

EID: 84892749999     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft209     Document Type: Review

References (106)

1. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-589
2. Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost 2010; 36: 34-40
3. Molino D, De Lucia D, Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol 2006; 26: 46-51
4. Mezzano D, Pais EO, Aranda E et al. Inflammation, not hyper-homocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60: 1844-1850
5. Glorieux G, Cohen G, Jankowski J et al. Platelet/leukocyte activation, inflammation, and uremia. Semin Dial 2009; 22: 423-427
6. Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis 2010; 17: 420-427
7. Moal V, Brunet P, Dou L et al. Impaired expression of glyco-proteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 2003; 18: 1834-1841
8. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev 2011; 25: 271-278
9. Kaufman JS, O'Connor TZ, Zhang JH et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14: 2313-2321
10. Parikh AM, Spencer FA, Lessard D et al. Venous thromboembo-lism in patients with reduced estimated GFR: a population-based perspective. Am J Kidney Dis 2011; 58: 746-755
11. Di Minno G, Martinez J, McKean ML et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-559
12. Eknoyan G, Brown CH, 3rd. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine tri-phosphatase. Am J Nephrol 1981; 1: 17-23
13. Smith MC, Dunn MJ. Impaired platelet thromboxane production in renal failure. Nephron 1981; 29: 133-137
14. Bloom A, Greaves M, Preston FE et al. Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic hae-modialysis. Br J Haematol 1986; 62: 143-149
15. Wratten ML, Tetta C, De Smet R et al. Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif 1999; 17: 134-141
16. Thekkedath UR, Chirananthavat T, Leypoldt JK et al. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol 2006; 81: 915-926
17. Rabiner SF, Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970; 49: 346-351
18. Horowitz HI. Uremic toxins and platelet function. Arch Intern Med 1970; 126: 823-826
19. Horowitz HI, Stein IM, Cohen BD et al. Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 1970; 49: 336-345
20. Remuzzi G, Livio M, Marchiaro G et al. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978; 22: 347-353
21. Sirolli V, Ballone E, Di Stante S et al. Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane. Int J Artif Organs 2002; 25: 529-537
22. Remuzzi G, Marchesi D, Livio M et al. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res 1978; 13: 1007-1015
23. Vigano G, Gotti E, Comberti E et al. Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 971-974
24. Brunini TM, Mendes-Ribeiro AC, Ellory JC et al. Platelet nitric oxide synthesis in uremia and malnutrition: a role for L-argi-nine supplementation in vascular protection? Cardiovasc Res 2007; 73: 359-367
25. Mezzano D, Tagle R, Panes O et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 312-321
26. Benigni A, Boccardo P, Galbusera M et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22: 668-676
27. Gawaz MP, Dobos G, Spath M et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5: 36-46
28. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996; 27: 355-364
29. Janson PA, Jubelirer SJ, Weinstein MJ et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980; 303: 1318-1322
30. Mannucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-argi-nine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12
31. Kyrle PA, Stockenhuber F, Brenner B et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. Thromb Haemost 1988; 60: 205-208
32. Defreyn G, Dauden MV, Machin SJ et al. A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. Thromb Res 1980; 19: 695-699
33. Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 2009; 22: 279-286
34. Fernandez F, Goudable C, Sie P et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-148
35. Howard AD, Moore J, Jr, Welch PG et al. Analysis of the quantitative relationship between anemia and chronic renal failure. Am J Med Sci 1989; 297: 309-313
36. Gaarder A, Jonsen J, Laland S et al. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
37. Martin W, Villani GM, Jothianandan D et al. Blockade of endo-thelium-dependent and glyceryl trinitrate-induced relaxation of rabbit aorta by certain ferrous hemoproteins. J Pharmacol Exp Ther 1985; 233: 679-685
38. Livio M, Gotti E, Marchesi D et al. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-1015
39. Moia M, Mannucci PM, Vizzotto L et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2: 1227-1229
40. Vigano G, Benigni A, Mendogni D et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991; 18: 44-49
41. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
42. Fass RJ, Copelan EA, Brandt JT et al. Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis 1987; 155: 1242-1248
43. Shattil SJ, Bennett JS, McDonough M et al. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 1980; 65: 329-337
44. Gaspari F, Vigano G, Orisio S et al. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxy-genase inhibition. J Clin Invest 1987; 79: 1788-1797
45. Pawlak K, Pawlak D, Mysliwiec M. Oxidative stress effects fibri-nolytic system in dialysis uraemic patients. Thromb Res 2006; 117: 517-522
46. Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial 2003; 16: 245-256
47. Monreal M, Falga C, Valle R et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119: 1073-1079
48. Falga C, Capdevila JA, Soler S et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007; 98: 771-776
49. Wattanakit K, Cushman M, Stehman-Breen C et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19: 135-140
50. Folsom AR, Lutsey PL, Astor BC et al. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant 2010; 25: 3296-3301
51. Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med 2009; 15: 408-412
52. Cook DJ, Crowther MA, Meade MO et al. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005; 20: 309-313
53. Ocak G, Verduijn M, Vossen CY et al. Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. J Thromb Haemost 2010; 8: 2428-2435
54. Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92
55. de la Serna G. Fibrinogen: a new major risk factor for cardiovascular disease. A review of the literature. J Fam Pract 1994; 39: 468-477
56. Pawlak K, Tankiewicz J, Mysliwiec M et al. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment. Blood Coagul Fibri-nolysis 2009; 20: 590-594
57. Cetin O, Bekpinar S, Unlucerci Y et al. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol 2006; 65: 97-102
58. Chu AJ. Tissue factor mediates inflammation. Arch Biochem Biophys 2005; 440: 123-132
59. Matsuo T, Koide M, Kario K et al. Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis 1997; 27: 163-167
60. Takagi M, Wada H, Mukai K et al. Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis. Clin Appl Thromb Hemost 1999; 5: 113-116
61. Tomura S, Nakamura Y, Deguchi F et al. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991; 64: 81-90
62. Tay KH, Lip GY. What 'drives' the link between the renin-angiotensin- aldosterone system and the prothrombotic state in hypertension? Am J Hypertens 2008; 21: 1278-1279
63. Huang Y, Noble NA. PAI-1 as a target in kidney disease. Curr Drug Targets 2007; 8: 1007-1015
64. Sloand EM, Bern MM, Kaldany A. Effect on platelet function of hypoalbuminemia in peritoneal dialysis. Thromb Res 1986; 44: 419-425
65. Jankowski J, van der Giet M, Jankowski V et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003; 112: 256-264
66. Bonomini M, Dottori S, Amoroso L et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 2: 1275-1281
67. Camaioni C, Gustapane M, Cialdella P et al. Microparticles and microRNAs: new players in the complex field of coagulation. Intern Emerg Med 2011
68. Jourde-Chiche N, Dou L, Sabatier F et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009; 7: 1576-1584
69. Mohandas R, Segal MS. Endothelial progenitor cells and endothelial vesicles-what is the significance for patients with chronic kidney disease? Blood Purif 2010; 29: 158-162
70. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441
71. Piazza G, Goldhaber SZ, Lessard DM et al. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost 2011; 106: 1095-1102
72. Mahmoodi BK, Gansevoort RT, Veeger NJ et al. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301: 1790-1797
73. Daniel L, Dou L, Berland Y et al. Circulating microparticles in renal diseases. Nephrol Dial Transplant 2008; 23: 2129-2132
74. Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res 2010; 125: S46-S48
75. Connor DE, Exner T, Ma DD et al. Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT Blood Coagul Fibrinolysis 2009; 20: 558-564
76. Key NS. Analysis of tissue factor positive microparticles. Thromb Res 2010; 125: S42-S45
77. Landry P, Plante I, Ouellet DL et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16: 961-966
78. Kondkar AA, Bray MS, Leal SM et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8: 369-378
79. Ple H, Maltais M, Corduan A et al. Alteration of the platelet transcriptome in chronic kidney disease. Thromb Haemost 2012; 108: 605-615
80. Brunet P, Aillaud MF, San Marco M et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48: 794-800
81. Chew SL, Lins RL, Daelemans R et al. Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant 1992; 7: 1194-1198
82. Prakash R, Miller CC, III, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26: 347-352
83. Adler S, Szczech L, Qureshi A et al. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemo-dialysis patients but do not predict thrombosis. Clin Nephrol 2001; 56: 428-434
84. Molino D, De Lucia D, Marotta R et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005; 68: 1223-1229
85. Schwab SJ, Harrington JT, Singh A et al. Vascular access for he-modialysis. Kidney Int 1999; 55: 2078-2090
86. Montagnana M, Meschi T, Borghi L et al. Thrombosis and occlusion of vascular access in hemodialyzed patients. Semin Thromb Hemost 2011; 37: 946-954
87. Girndt M, Heine GH, Ulrich C et al. Gene polymorphism association studies in dialysis: vascular access. Semin Dial 2007; 20: 63-67
88. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophy-siology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012; 7: 513-520
89. Cuker A. Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis 2011; 31: 353-366
90. Syed S, Reilly RF. Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol 2009; 5: 501-511
91. Cuker A, Rux AH, Hinds JL et al. Novel diagnostic assays for heparin-induced thrombocytopenia. Blood 2013; 121: 3727-3732
92. Cuker A, Cines DB. How I treat heparin-induced thrombocyto-penia. Blood 2012; 119: 2209-2218
93. Kodityal S, Nguyen PH, Kodityal A et al. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006; 21: 86-92
94. Davenport A. What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol 2011; 7: 499-508
95. Gubensek J, Kovac J, Benedik M et al. Long-term citrate antic-oagulation in chronic hemodialysis patients. Ther Apher Dial 2011; 15: 278-282
96. Alpert MA. Cardiovascular factors influencing survival in dialysis patients. Adv Perit Dial 1996; 12: 110-119
97. Prichard S, Sniderman A, Cianflone K et al. Cardiovascular disease in peritoneal dialysis. Perit Dial Int 1996; 16: S19-S22
98. Opatrny K, Jr, Opatrna S, Vit L et al. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis. Am J Nephrol 1998; 18: 186-192
99. Preloznik Zupan I, Sabovic M, Salobir B et al. Characterization of the pro-thrombotic state in CAPD patients. Ren Fail 2008; 30: 597-602
100. Alwakeel J, Gader AM, Hurieb S et al. Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis. Int Urol Nephrol 1996; 28: 255-261
101. Soyoral YU, Demir C, Begenik H et al. Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis. Clin Appl Thromb Hemost 2012; 18: 185-188
102. Bilgin AU, Karadogan I, Artac M et al. Hemodialysis shortens long in vitro closure times as measured by the PFA-100. Med Sci Monit 2007; 13: CR141-CR145
103. Zupan IP, Sabovic M, Salobir B et al. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003; 42: 746-751
104. Waki K, Hayashi A, Ikeda S et al. Measuring platelet aggregation in dialysis patients with a whole blood aggregometer by the screen filtration pressure method. Ther Apher Dial 2011; 15: 203-206
105. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-440
106. Paniccia R, Fedi S, Carbonetto F et al. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test. Anesthesiology 2003; 99: 54-59